22777-05-5

Basic information

• Product Name: 5-Methyl-[1,4]diazepane
• Synonyms: 5-Methyl-[1,4]diazepane;1H-1,4-Diazepine, hexahydro-5-Methyl-;hexahydro-5-methyl-1H-1,4-Diazepine
• CAS NO: 22777-05-5
• Molecular Formula: C₆H₁₄N₂
• Molecular Weight: 114.19
• Product Categories: pharmacetical
• Mol File: 22777-05-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 174.5 °C at 760 mmHg
• Flash Point: 61.5 °C
• Appearance: /
• Density: 0.838g/cm³
• Vapor Pressure: 1.2mmHg at 25°C
• Refractive Index: 1.419
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.78±0.40(Predicted)
• CAS DataBase Reference: 5-Methyl-[1,4]diazepane(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methyl-[1,4]diazepane(22777-05-5)
• EPA Substance Registry System: 5-Methyl-[1,4]diazepane(22777-05-5)

Safety Data

• RIDADR: UN3265
• Hazardous Substances Data: 22777-05-5(Hazardous Substances Data)

Usage

General Description

5-Methyl-[1,4]diazepane is a chemical compound that belongs to the diazepane family, which is a class of 7-membered heterocyclic compounds containing a diazepane ring. It is also known by its chemical formula C6H12N2. 5-Methyl-[1,4]diazepane is a saturated, nitrogen-containing ring that is commonly used in the pharmaceutical industry for its potential therapeutic properties. It has been studied for its potential use as an anti-anxiety and anti-convulsant medication, as well as in the treatment of various neurological disorders. Additionally, it has been investigated for its potential as a building block for the synthesis of novel drug candidates. While further research is needed to fully understand its pharmacological properties and potential applications, 5-Methyl-[1,4]diazepane shows promise as a valuable chemical compound in the field of medicine and pharmaceuticals.

InChI:InChI=1/C6H14N2/c1-6-2-3-7-4-5-8-6/h6-8H,2-5H2,1H3

Upstream product

• 107-80-2 1,3-dibromobutane 
• 140-28-3 N,N'-Dibenzylethylenediamine 

Downstream Products

• 194032-42-3 tert-butyl 5-methyl-1,4-diazepane-1-carboxylate 
• 1439358-17-4 C₁₉H₂₅N₅O₃S 
• 217972-87-7 benzyl 5-methyl-1,4-diazepane-1-carboxylate 

Relevant articles and documents

QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES

The present invention relates to a quinazolinone or isoquinolinone derivative of formula I, wherein R1 is C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-3alkyl, C2-6alkenyl, C2-6alkynyl, said C1-6alkyl, C3-6cycloalkyl and C3-6cycloalkylC1-3alkyl being optionally substituted with hydroxy, C1-6alkyloxy, cyano or one or more halogens; R2 is C6-10aryl optionally substituted with one to three substituents selected from halogen, hydroxy, cyano, C1-6alkyl, C3-6cycloalkyl, C1-6alkyloxy and C3-6cycloalkyloxy, said C1-6alkyl, C3-6 cycloalkyl, C1-6 alkyloxy and C3-6Cycloalkyloxy being optionally substituted with one or more halogens; or R2 is a 5-10 membered heteroaryl ring system comprising a heteroatom selected from N, O and S and optionally substituted with a substituent selected from methyl, C1-6alkyloxy and halogen; or R2 is C4-7cycloalkyl; R3 is an optional substituent selected from C1-6alkyl, C1-6alkyloxy and halogen, said C1-6alkyl and C1-6alkyloxy being optionally substituted with one or more halogens; R4 is a group located at the 6- or 7- position of the quinazolinone or isoquinolinone ring having the formula Il, wherein R5 together with one of R6 forms a 4-8 membered saturated or unsaturated heterocyclic ring optionally comprising a further heteroatomic moiety selected from O, S and NR9, said heterocyclic ring being optionally substituted with one or two substituents selected from methyl, halogen, hydroxy and oxo or R5 together with one of R7 and R8 forms a 6-8 membered heterocyclic ring optionally substituted with one or two substituents selected from methyl, halogen, hydroxy and oxo; Each R6 is independently H, halogen or C1-4alkyl optionally substituted with halogen or SO2CH3 or one of R6 together with R5 forms a 4-8 membered saturated or unsaturated heterocyclic ring optionally comprising a further heteroatomic moiety selected from O, S and NR9, said heterocyclic ring being optionally substituted with one or two substituents selected from methyl, halogen, hydroxy and oxo; R7 and R8 are independently H, C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylc1-3alkyl, cyanoC1-3alkyl, C6-10aryl, C6-10arylC1-3alkyl, C1-3alkyloxyC1-3alkyl or C1-6acyl said C1-6alkyl, C3-6cycloalkyl and C3-6cycloalkylC1-3alkyl being optionally substituted with hydroxy, 1 or more halogens or diC1-2alkylamino; or R7 and R8 together with the nitrogen to which they are bonded form a 4-8 membered saturated or unsaturated heterocyclic ring optionally comprising a further heteroatomic moiety selected from O, S and NR10, said heterocyclic ring being optionally substituted with one or two substituents selected from C1-6alkyl, halogen, hydroxy,

2-Pyrimidineamine derivatives and processes for their preparation

Compounds of general formula (1) are described wherein: Ar is an optionally substituted aromatic group; R2 is a hydrogen or halogen atom or a group -X1-R2a where X1 is a direct bond or a linker atom or group, and R2a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R3 is an optionally substituted heterocycloalkyl group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective protein tyrosine kinase inhibitors, particularly the kinases ZAP-70 and syk and are of use in the prophylaxis and treatment of immune or allergic diseases and diseases involving inappropriate platelet activation.